Why the study?
This study investigated the prevalence of inherited thrombophilia, the risk of venous thromboembolism, and the benefit of low molecular weight heparin prophylaxis in children with acute lymphoblastic leukaemia.
Does low molecular weight heparin prophylaxis prevent venous thromboembolism in children with acute lymphoblastic leukaemia and inherited thrombophilia?
Does low molecular weight heparin prophylaxis prevent venous thromboembolism in children with acute lymphoblastic leukaemia and inherited thrombophilia?
Routine evaluation for inherited thrombophilia followed by LMWH prophylaxis may prevent severe VTE in at-risk children with acute lymphoblastic leukemia.
This study investigated the prevalence of inherited thrombophilia, risk of venous thromboembolism (VTE) and benefit of low molecular weight heparin prophylaxis in 476 Israeli children with acute lymphoblastic leukaemia (ALL) treated between 2004 and 2016. Thrombophilia was found in 15·5%. Arab children had a higher prevalence of F5 R506Q (factor V Leiden) than Jewish children (19·4% vs. 2·9%, P < 0·01). Patients with thrombophilia had higher VTE rates VTE (26·5% vs. 5·6%, P < 0·001). None of the thrombophilic children given prophylaxis had severe VTE. Routine evaluation for inherited thrombophilia followed by thromboprophylaxis when findings are positive may benefit at-risk patients with ALL.
No takes yet. Share an insight, caveat, or question.
Barzilai‐Birenboim et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: